Online inquiry

IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6056MR)

This product GTTS-WQ6056MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL6 gene. The antibody can be applied in Giant cell arteritis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000600.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3569
UniProt ID P05231
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ6056MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14686MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SCT-400
GTTS-WQ610MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 6A3-IgG4
GTTS-WQ3037MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ4458MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-901608
GTTS-WQ14774MR IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-40
GTTS-WQ7134MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA FE 999302
GTTS-WQ15683MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA VEGF Trap
GTTS-WQ4170MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BI-754111
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW